risks of glp 1 agonists Do The Benefits GLP-1 Drugs OutWeigh the Negatives? of the metabolic effect and
Description
Acknowledgments Not applicable
Kaku K, Yamada Y, Watada H, et al
The first GLP-1 injectable receptor agonist exenatide was approved by the U.S
The guidance is in response to recent case reports and large case series that have shown a risk of retained gastric contents and cases of pulmonary aspiration during sedation for endoscopic procedures or general anaesthesia in individuals treated with GLP-1RAs or GLP-1/GIPRAs
Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial
